S&P 500   4,564.57 (-0.65%)
DOW   36,192.36 (-0.15%)
QQQ   385.26 (-1.20%)
AAPL   189.04 (-1.15%)
MSFT   368.24 (-1.67%)
META   318.11 (-2.07%)
GOOGL   128.59 (-2.48%)
AMZN   144.32 (-1.84%)
TSLA   236.75 (-0.87%)
NVDA   452.87 (-3.16%)
NIO   7.32 (+2.38%)
BABA   73.06 (-1.26%)
AMD   118.40 (-2.46%)
T   16.58 (-1.07%)
F   10.69 (+1.04%)
MU   74.11 (-2.40%)
CGC   0.75 (+21.50%)
GE   121.76 (-0.60%)
DIS   92.00 (-0.63%)
AMC   7.37 (+7.43%)
PFE   29.34 (+1.49%)
PYPL   59.97 (+0.54%)
XOM   102.44 (-0.53%)
S&P 500   4,564.57 (-0.65%)
DOW   36,192.36 (-0.15%)
QQQ   385.26 (-1.20%)
AAPL   189.04 (-1.15%)
MSFT   368.24 (-1.67%)
META   318.11 (-2.07%)
GOOGL   128.59 (-2.48%)
AMZN   144.32 (-1.84%)
TSLA   236.75 (-0.87%)
NVDA   452.87 (-3.16%)
NIO   7.32 (+2.38%)
BABA   73.06 (-1.26%)
AMD   118.40 (-2.46%)
T   16.58 (-1.07%)
F   10.69 (+1.04%)
MU   74.11 (-2.40%)
CGC   0.75 (+21.50%)
GE   121.76 (-0.60%)
DIS   92.00 (-0.63%)
AMC   7.37 (+7.43%)
PFE   29.34 (+1.49%)
PYPL   59.97 (+0.54%)
XOM   102.44 (-0.53%)
S&P 500   4,564.57 (-0.65%)
DOW   36,192.36 (-0.15%)
QQQ   385.26 (-1.20%)
AAPL   189.04 (-1.15%)
MSFT   368.24 (-1.67%)
META   318.11 (-2.07%)
GOOGL   128.59 (-2.48%)
AMZN   144.32 (-1.84%)
TSLA   236.75 (-0.87%)
NVDA   452.87 (-3.16%)
NIO   7.32 (+2.38%)
BABA   73.06 (-1.26%)
AMD   118.40 (-2.46%)
T   16.58 (-1.07%)
F   10.69 (+1.04%)
MU   74.11 (-2.40%)
CGC   0.75 (+21.50%)
GE   121.76 (-0.60%)
DIS   92.00 (-0.63%)
AMC   7.37 (+7.43%)
PFE   29.34 (+1.49%)
PYPL   59.97 (+0.54%)
XOM   102.44 (-0.53%)
S&P 500   4,564.57 (-0.65%)
DOW   36,192.36 (-0.15%)
QQQ   385.26 (-1.20%)
AAPL   189.04 (-1.15%)
MSFT   368.24 (-1.67%)
META   318.11 (-2.07%)
GOOGL   128.59 (-2.48%)
AMZN   144.32 (-1.84%)
TSLA   236.75 (-0.87%)
NVDA   452.87 (-3.16%)
NIO   7.32 (+2.38%)
BABA   73.06 (-1.26%)
AMD   118.40 (-2.46%)
T   16.58 (-1.07%)
F   10.69 (+1.04%)
MU   74.11 (-2.40%)
CGC   0.75 (+21.50%)
GE   121.76 (-0.60%)
DIS   92.00 (-0.63%)
AMC   7.37 (+7.43%)
PFE   29.34 (+1.49%)
PYPL   59.97 (+0.54%)
XOM   102.44 (-0.53%)

BioMarin Pharmaceutical Stock Price, News & Analysis (NASDAQ:BMRN)

$94.16
+1.74 (+1.88%)
(As of 02:51 PM ET)
Compare
Today's Range
$92.26
$94.97
50-Day Range
$76.22
$92.42
52-Week Range
$76.02
$117.77
Volume
1.50 million shs
Average Volume
1.39 million shs
Market Capitalization
$17.74 billion
P/E Ratio
122.29
Dividend Yield
N/A
Price Target
$112.65

BioMarin Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.61 Rating Score
Upside/​Downside
20.0% Upside
$112.65 Price Target
Short Interest
Healthy
1.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.93
Upright™ Environmental Score
News Sentiment
1.05mentions of BioMarin Pharmaceutical in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
84.75%
From $1.18 to $2.18 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Medical Sector

75th out of 951 stocks

Pharmaceutical Preparations Industry

21st out of 439 stocks


BMRN stock logo

About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BMRN Stock Price History

BMRN Stock News Headlines

Is This The Most Overlooked Gold Investment Strategy of 2024?
There is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks.
Is This The Most Overlooked Gold Investment Strategy of 2024?
There is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks.
Oppenheimer Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)
BioMarin: Keeping Bullish View After Q3 Earnings
See More Headlines
Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BMRN
CUSIP
09061G10
Employees
3,082
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$112.65
High Stock Price Target
$185.00
Low Stock Price Target
$78.00
Potential Upside/Downside
+21.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.61
Research Coverage
23 Analysts

Profitability

Net Income
$141.56 million
Pretax Margin
6.56%

Debt

Sales & Book Value

Annual Sales
$2.31 billion
Cash Flow
$1.47 per share
Book Value
$26.00 per share

Miscellaneous

Free Float
184,902,000
Market Cap
$17.41 billion
Optionable
Optionable
Beta
0.40

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report














BMRN Stock Analysis - Frequently Asked Questions

Should I buy or sell BioMarin Pharmaceutical stock right now?

23 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 9 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BMRN shares.
View BMRN analyst ratings
or view top-rated stocks.

What is BioMarin Pharmaceutical's stock price target for 2024?

23 analysts have issued 1 year price targets for BioMarin Pharmaceutical's shares. Their BMRN share price targets range from $78.00 to $185.00. On average, they expect the company's stock price to reach $112.65 in the next twelve months. This suggests a possible upside of 20.0% from the stock's current price.
View analysts price targets for BMRN
or view top-rated stocks among Wall Street analysts.

How have BMRN shares performed in 2023?

BioMarin Pharmaceutical's stock was trading at $103.49 at the start of the year. Since then, BMRN stock has decreased by 9.3% and is now trading at $93.85.
View the best growth stocks for 2023 here
.

Are investors shorting BioMarin Pharmaceutical?

BioMarin Pharmaceutical saw a decline in short interest in November. As of November 15th, there was short interest totaling 3,080,000 shares, a decline of 6.4% from the October 31st total of 3,290,000 shares. Based on an average daily volume of 1,520,000 shares, the short-interest ratio is currently 2.0 days.
View BioMarin Pharmaceutical's Short Interest
.

When is BioMarin Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our BMRN earnings forecast
.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its earnings results on Wednesday, November, 1st. The biotechnology company reported $0.26 EPS for the quarter, missing analysts' consensus estimates of $0.28 by $0.02. The biotechnology company earned $581.33 million during the quarter, compared to analysts' expectations of $603.51 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 4.45% and a net margin of 6.36%.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical updated its fourth quarter earnings guidance on Wednesday, November, 1st. The company provided earnings per share (EPS) guidance of $0.08-0.28 for the period, compared to the consensus earnings per share estimate of $0.27. The company issued revenue guidance of $617-697 million, compared to the consensus revenue estimate of $652.66 million.

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (9.77%), Barclays PLC (2.96%), Ameriprise Financial Inc. (2.74%), Fort Washington Investment Advisors Inc. OH (0.70%), Charles Schwab Investment Management Inc. (0.69%) and Northern Trust Corp (0.65%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier and V Bryan Lawlis.
View institutional ownership trends
.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BMRN) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -